In 2021, 30 EU/EEA countries reported 3 864 cases of hepatitis A (Table 1). The EU/EEA notification rate was 0.9 cases per 100 000 population. In 2021, both the lowest number of reported cases and the lowest notification rate were reported since the beginning of EU-level hepatitis A surveillance in 2007. The total number of hepatitis A cases reported in EU/EEA countries in 2021 represented a decrease of 65.7% and 12.3% compared to 2019 and 2020, respectively.
This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring and surveillance activities carried out in 2021 in 27 MSs, the United Kingdom (Northern Ireland) and nine non-MSs.
The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
Clusters and outbreaks of hepatitis A virus (HAV) genotype IB with four unique but closely related HAV sequences have been reported in six European Union (EU) countries and in the United Kingdom (UK).